Neuropair

NeuroPair works on a treatment to regenerate and re-connect neurons after spinal cord injury. Spinal cord injury afflicts 17,000 Americans and 700,000 people worldwide each year with devastating and irreversible consequences. There is no effective therapy. Prognoses are often tragic, and costs exceed $2M (US and EU) in the first 5 years of care. For decades, the dream of repairing the spinal cord has been elusive.

Recent studies, however, show that new axonal growth and formation of functional circuits are possible under the right conditions: a favorable biophysical environment in direct contact with surviving nerve endings. Chances for recovery increase greatly if such an environment can be generated rapidly after injury.

Fibermag® is the first approach that protects and guides the body’s own tissue to regenerate lost function. The treatment we envision is a minimally invasive implant that automatically adjusts to the different injury types shapes of individual patients. There is no need to surgically match the injured cord to an implant - a key improvement over rigid implants. Our first procedure will be an injection for the stabilization of sub-acute spinal cord injuries, when the patient has been stabilized and the injured cord decompressed. If successful, the treatment will be extended also to patients with chronic spinal cord injury.

See below for how Fibermag® works.

We want to help patients regain function and avoid long-term paralysis.

A New Hope for Spinal Cord Injury Patients

NeuroPair’s goal is a minimally invasive, patient-specific implant for a flexible and fast treatment for protecting, healing, and regrowing neurons damaged during spinal cord injury.

Its patented Fibermag® technology (US 11,083,907, others pending) builds on recent scientific evidence of successful functional recovery – see for instance the episode of CBS’s 60 Minutes “To Walk Again” by Anderson Cooper of May 11, 2025:

Fibermag® is a liquid hydrogel with magnetically aligning nanoparticles that create a nerve-guiding fiber scaffold in situ. The injectable implant instantly adapts to the natural geometry of a lesion, without any gaps: Direct connections are established between the fibers of the implant and surviving axons on both ends of the injury, without having to surgically match the injured cord to an implant – direct contact is essential for successful graft-host interaction. The formulation is also compatible with treatment options such as stem cells, neuroprotective and bioactive growth factors, electric stimulation.

Learn More

“You never change things by fighting the existing reality.
To change something, build a new model that makes the existing model obsolete”

— R. Buckminster Fuller

The simple and award-winning, shape-conforming nature of NeuroPair’s injectable hydrogel implant can perhaps most intuitively be illustrated by the analogy of an engine that would automatically install itself in a car from ‘liquid metal’, or a ‘mimetic polyalloy’.
See the animation below.

After transferring it into the empty engine compartment (= the injured lesion within the spinal cord), it would adjust itself to the available engine space of any type of car (= any patient), establish direct connections with existing attachment points, linkages and electrical contacts (= the surviving nerve endings on both ends of the spinal cord), and would not require any modifications of the car body (= no resection of the cord to place an implant).

Text box item sample content